Treatments for Amyloidosis

 Treatments for Amyloidosis

Drugs used to treat Amyloidosis

 

dexamethasone

prednisone

daratumumab / hyaluronidase

Darzalex Faspro

colchicine

 

 

What is Amyloidosis?

 

Amyloidosis is a rare and complex group of diseases that occurs when a protein called amyloid builds up in organs and tissues. Amyloid proteins are normally soluble, but in amyloidosis, they misfold and clump together, forming insoluble fibrils that deposit in tissues. These deposits disrupt normal organ function, and without treatment, amyloidosis can be life-threatening. The condition can affect multiple organs, including the heart, kidneys, liver, spleen, nervous system, and digestive tract.

 

Types of Amyloidosis

Amyloidosis can be classified into several types, primarily based on the type of amyloid protein involved and its origin:

 

1. AL (Light Chain) Amyloidosis:

   - This is the most common form of amyloidosis and is caused by abnormal plasma cells in the bone marrow that produce an excess of light chain proteins (components of antibodies).

   - These light chains misfold into amyloid fibrils, which then accumulate in organs, commonly the heart, kidneys, liver, and nervous system.

   - AL amyloidosis is often associated with multiple myeloma, a type of blood cancer.

 

2. AA (Serum Amyloid A) Amyloidosis:

   - This type is associated with chronic inflammatory diseases or infections, like rheumatoid arthritis or tuberculosis.

   - AA amyloidosis involves the serum amyloid A protein, produced by the liver in response to inflammation. When chronic inflammation persists, this protein misfolds and accumulates.

   - It primarily affects the kidneys but can also impact the liver, spleen, and intestines.

 

3. ATTR (Transthyretin) Amyloidosis:

   - ATTR amyloidosis is linked to transthyretin, a protein produced by the liver that usually transports thyroid hormone and vitamin A.

   - There are two main forms:

     - Hereditary ATTR Amyloidosis: This results from a genetic mutation in the TTR gene, leading to unstable transthyretin proteins that form amyloid deposits. This form can affect the heart and peripheral nerves.

     - Wild-type (senile) ATTR Amyloidosis: Occurs without a genetic mutation and mainly affects elderly men, with deposits primarily in the heart.

 

4. Localized Amyloidosis:

   - In this form, amyloid deposits occur in isolated areas, like the skin, lungs, or bladder, without systemic involvement. It’s usually less severe.

 

5. Other Rare Forms:

   - These include dialysis-related amyloidosis, where beta-2 microglobulin protein deposits in patients undergoing long-term dialysis, and various types of hereditary amyloidosis caused by rare protein mutations.

 

Symptoms

Symptoms vary widely depending on the organs affected, but some common signs include:

 

- Heart: Cardiomyopathy, heart failure, arrhythmias, shortness of breath, swelling in the legs and ankles.

- Kidneys: Proteinuria (protein in urine), leading to nephrotic syndrome, kidney failure.

- Nervous System: Peripheral neuropathy (numbness, tingling, pain in extremities), carpal tunnel syndrome, autonomic neuropathy (digestive issues, blood pressure irregularities).

- Gastrointestinal Tract: Difficulty swallowing, diarrhea or constipation, weight loss, feeling of fullness.

- Other General Symptoms: Fatigue, weakness, unintentional weight loss, swelling in the tongue (macroglossia), bruising, or purpura around the eyes.

 

Diagnosis

Diagnosing amyloidosis involves a combination of laboratory tests, imaging, and biopsies:

 

1. Blood and Urine Tests: To detect abnormal protein levels and organ dysfunction, such as elevated serum free light chains (for AL amyloidosis) or high serum amyloid A protein (for AA amyloidosis).

2. Imaging: Echocardiograms and cardiac MRI for heart involvement, CT or ultrasound for other organ assessment.

3. Biopsy: The definitive diagnosis involves identifying amyloid deposits in tissue samples (usually from the affected organ, bone marrow, or abdominal fat). Staining with Congo red dye under a microscope shows green birefringence, confirming amyloid presence.

4. Genetic Testing: Often used to identify hereditary forms, especially in suspected ATTR amyloidosis.

 

Treatment Options

Treatment varies depending on the type and severity of amyloidosis:

 

1. AL Amyloidosis:

   - Chemotherapy: To target the abnormal plasma cells producing the amyloid-forming light chains.

   - Stem Cell Transplant: For eligible patients, autologous stem cell transplant can help rebuild healthy bone marrow after high-dose chemotherapy.

   - Newer Drugs: Medications like daratumumab and bortezomib target specific proteins involved in amyloid production and have shown promise.

 

2. AA Amyloidosis:

   - Anti-Inflammatory Drugs: Treating the underlying inflammatory condition with medications like NSAIDs, corticosteroids, or biologics to reduce serum amyloid A production.

   - Lifestyle Management: Diet and lifestyle adjustments to manage kidney involvement.

 

3. ATTR Amyloidosis:

   - TTR Stabilizers: Tafamidis and diflunisal stabilize the transthyretin protein, reducing amyloid formation.

   - Gene Silencers: New therapies like patisiran and inotersen suppress transthyretin protein production, slowing disease progression.

   - Liver Transplant: In hereditary ATTR amyloidosis, liver transplants may be considered to reduce mutated protein production.

 

4. Symptom Management:

   - Diuretics for fluid management in heart or kidney amyloidosis, medications for pain relief, and therapies to manage neuropathy and digestive symptoms.

 

Prognosis

The prognosis depends on the type of amyloidosis, the organs affected, and the timeliness of diagnosis. AL amyloidosis has a more guarded prognosis due to rapid organ damage if untreated, while AA amyloidosis outcomes can improve significantly with good control of the underlying inflammatory condition. ATTR amyloidosis generally progresses slowly, especially in wild-type forms, but new treatments are improving outcomes for both hereditary and wild-type forms.

 

Summary

Amyloidosis is a serious, progressive disease requiring early diagnosis and a personalized treatment approach. While treatments are advancing, amyloidosis remains challenging to manage, and patients typically require a multidisciplinary healthcare team for comprehensive care.